Veracyte Inc (VCYT)

$48.69 +0.89 (1.86%)
Market Cap 3.81B
Revenue (ttm) 517.15M
Net Income (ttm) 66.35M
EPS (ttm) N/A
PE Ratio 33.00
Forward PE 37.54
Profit Margin 12.83%
Debt to Equity Ratio 0.00
Volume 1,451,700
Avg Vol 993,702
Day's Range N/A - N/A
Shares Out 79.79M
Stochastic %K 78%
Beta 1.98
Analysts Strong Sell
Price Target $46.90

Company Profile

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was f...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 650 243 6300
Fax: 650 243 6388
Address:
6000 Shoreline Court, Suite 300, South San Francisco, United States
OptionsTrader8364
OptionsTrader8364 Jun. 3 at 6:22 PM
$VCYT bought in- let’s go! Large room for growth
0 · Reply
Nigel11
Nigel11 Jun. 3 at 6:14 PM
$SOFI pay attention to $VCYT
0 · Reply
Following_the_trend
Following_the_trend Jun. 3 at 6:08 PM
$VCYT Continues it's upward move
0 · Reply
whiteavid
whiteavid Jun. 1 at 3:07 PM
$VCYT let’s goooo!!
0 · Reply
whiteavid
whiteavid Jun. 1 at 12:35 PM
$VCYT
0 · Reply
whiteavid
whiteavid Jun. 1 at 11:32 AM
$VCYT investors call in an hour
0 · Reply
whiteavid
whiteavid May. 30 at 2:07 PM
$VCYT bbc interview now
0 · Reply
ChillllinTheMost
ChillllinTheMost May. 29 at 9:36 PM
$VCYT https://www.theguardian.com/society/2026/may/29/groundbreaking-genomic-test-spare-breast-cancer-patients-chemotherapy-hormone-therapy Early next week should be interesting. 🔥
0 · Reply
HodlMaBeer
HodlMaBeer May. 29 at 6:22 AM
$VCYT sweet!! Lt hold wife's account Shes already doubled her position in $APGE
0 · Reply
ChillllinTheMost
ChillllinTheMost May. 28 at 3:38 PM
$VCYT looks like the initial data in the abstract is extremely positive. After the data is presented this weekend, next week should be interesting! Time to accumulate if you haven’t been. Lol. https://www.reuters.com/business/healthcare-pharmaceuticals/veracyte-genomic-test-identifies-breast-cancer-patients-who-can-skip-chemo-2026-05-27/
0 · Reply
Latest News on VCYT
Veracyte Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 8:10 AM EDT - 2 hours ago

Veracyte Transcript: Jefferies Global Healthcare Conference 2026

Veracyte Transcript: 46th Annual William Blair Growth Stock Conference

Jun 2, 2026, 3:00 PM EDT - 1 day ago

Veracyte Transcript: 46th Annual William Blair Growth Stock Conference

Veracyte Slides: 46th Annual William Blair Growth Stock Conference

Jun 2, 2026, 3:00 PM EDT - 1 day ago

Veracyte Slides: 46th Annual William Blair Growth Stock Conference

Veracyte assumed with an Outperform at Wolfe Research

2026-06-01T20:47:20.000Z - 2 days ago

Veracyte assumed with an Outperform at Wolfe Research

Veracyte Transcript: Study update

Jun 1, 2026, 8:30 AM EDT - 3 days ago

Veracyte Transcript: Study update

Veracyte Slides: Study update

Jun 1, 2026, 8:30 AM EDT - 3 days ago

Veracyte Slides: Study update

Veracyte announces U.S. commercial launch of Prosigna ROR test

2026-06-01T11:41:32.000Z - 3 days ago

Veracyte announces U.S. commercial launch of Prosigna ROR test

Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

Jun 1, 2026, 7:30 AM EDT - 3 days ago

Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

Veracyte announces results from Enzamet trial presented at 2026 ASCO meeting

2026-05-31T13:36:37.000Z - 4 days ago

Veracyte announces results from Enzamet trial presented at 2026 ASCO meeting

ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

May 30, 2026, 8:00 AM EDT - 5 days ago

ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

May 29, 2026, 3:15 PM EDT - 5 days ago

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

Veracyte genomic test identifies breast cancer patients who can skip chemo

May 27, 2026, 7:22 AM EDT - 8 days ago

Veracyte genomic test identifies breast cancer patients who can skip chemo

Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings

May 22, 2026, 8:00 AM EDT - 13 days ago

Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings

OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer

May 21, 2026, 6:00 PM EDT - 13 days ago

OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer

Veracyte to Participate in Upcoming Investor Conferences

May 19, 2026, 4:05 PM EDT - 15 days ago

Veracyte to Participate in Upcoming Investor Conferences

Veracyte’s TrueMRD Monitoring Test receives coverage from CMS

2026-05-15T15:14:38.000Z - 19 days ago

Veracyte’s TrueMRD Monitoring Test receives coverage from CMS

Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer

May 15, 2026, 9:00 AM EDT - 20 days ago

Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer

Veracyte price target raised to $42 from $40 at Canaccord

2026-05-07T06:56:24.000Z - 4 weeks ago

Veracyte price target raised to $42 from $40 at Canaccord

Veracyte price target raised to $52 from $48 at UBS

2026-05-07T03:55:46.000Z - 4 weeks ago

Veracyte price target raised to $52 from $48 at UBS

Veracyte Earnings Call Transcript: Q1 2026

May 5, 2026, 4:30 PM EDT - 4 weeks ago

Veracyte Earnings Call Transcript: Q1 2026

Veracyte Earnings release: Q1 2026

May 5, 2026, 4:30 PM EDT - 4 weeks ago

Veracyte Earnings release: Q1 2026

Veracyte Slides: Q1 2026

May 5, 2026, 4:30 PM EDT - 4 weeks ago

Veracyte Slides: Q1 2026

Veracyte Quarterly report: Q1 2026

May 5, 2026, 4:30 PM EDT - 4 weeks ago

Veracyte Quarterly report: Q1 2026

Veracyte Announces First Quarter 2026 Financial Results

May 5, 2026, 4:05 PM EDT - 4 weeks ago

Veracyte Announces First Quarter 2026 Financial Results

Veracyte announces new data at AUA 2026 on Decipher portfolio

2026-04-28T14:12:33.000Z - 5 weeks ago

Veracyte announces new data at AUA 2026 on Decipher portfolio

Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers

Apr 28, 2026, 9:00 AM EDT - 5 weeks ago

Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers

Veracyte Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 6 weeks ago

Veracyte Proxy statement: Proxy filing

Veracyte Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 6 weeks ago

Veracyte Proxy statement: Proxy filing

Veracyte price target lowered to $40 from $43 at Canaccord

2026-04-20T14:03:18.000Z - 6 weeks ago

Veracyte price target lowered to $40 from $43 at Canaccord

Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026

Apr 14, 2026, 4:05 PM EDT - 7 weeks ago

Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026

Veracyte initiated with a Buy at Jefferies

2026-04-12T23:52:05.000Z - 7 weeks ago

Veracyte initiated with a Buy at Jefferies

Veracyte price target lowered to $45 from $50 at Guggenheim

2026-03-30T11:52:33.000Z - 2 months ago

Veracyte price target lowered to $45 from $50 at Guggenheim

Veracyte names Kevin Haas as Chief Development and Technology Officer

2026-03-16T20:26:43.000Z - 2 months ago

Veracyte names Kevin Haas as Chief Development and Technology Officer

Veracyte Names Kevin Haas as Chief Development and Technology Officer

Mar 16, 2026, 4:15 PM EDT - 2 months ago

Veracyte Names Kevin Haas as Chief Development and Technology Officer

Veracyte Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 10:40 AM EDT - 3 months ago

Veracyte Transcript: Leerink Global Healthcare Conference 2026

Veracyte price target lowered to $37 from $48 at Morgan Stanley

2026-03-06T13:27:22.000Z - 3 months ago

Veracyte price target lowered to $37 from $48 at Morgan Stanley

Veracyte Transcript: 47th Annual Raymond James Institutional Investor Conference

Mar 3, 2026, 8:05 AM EST - 3 months ago

Veracyte Transcript: 47th Annual Raymond James Institutional Investor Conference

Veracyte Slides: 47th Annual Raymond James Institutional Investor Conference

Mar 3, 2026, 8:05 AM EST - 3 months ago

Veracyte Slides: 47th Annual Raymond James Institutional Investor Conference

Veracyte reports Q4 EPS 51c, consensus 41c

2026-02-25T22:15:11.000Z - 3 months ago

Veracyte reports Q4 EPS 51c, consensus 41c

Veracyte sees FY26 revenue $570M-$582M, consensus $570.3M

2026-02-25T22:14:18.000Z - 3 months ago

Veracyte sees FY26 revenue $570M-$582M, consensus $570.3M

Veracyte Earnings Call Transcript: Q4 2025

Feb 25, 2026, 4:30 PM EST - 3 months ago

Veracyte Earnings Call Transcript: Q4 2025

Veracyte Annual report: Q4 2025

Feb 25, 2026, 4:30 PM EST - 3 months ago

Veracyte Annual report: Q4 2025

Veracyte Earnings release: Q4 2025

Feb 25, 2026, 4:30 PM EST - 3 months ago

Veracyte Earnings release: Q4 2025

Veracyte Slides: Q4 2025

Feb 25, 2026, 4:30 PM EST - 3 months ago

Veracyte Slides: Q4 2025

Veracyte Annual report: Q4 2025

Feb 25, 2026, 4:30 PM EST - 3 months ago

Veracyte Annual report: Q4 2025

Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results

Feb 25, 2026, 4:05 PM EST - 3 months ago

Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results

Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium

Feb 24, 2026, 9:00 AM EST - 3 months ago

Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium

Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026

Feb 4, 2026, 5:15 PM EST - 4 months ago

Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026

Veracyte Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 15, 2026, 12:45 PM EST - 4 months ago

Veracyte Transcript: 44th Annual J.P. Morgan Healthcare Conference

Veracyte Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 15, 2026, 12:45 PM EST - 4 months ago

Veracyte Slides: 44th Annual J.P. Morgan Healthcare Conference

Veracyte reports preliminary Q4 revenue $138M-$140M, consensus $131.75M

2026-01-11T22:15:41.000Z - 5 months ago

Veracyte reports preliminary Q4 revenue $138M-$140M, consensus $131.75M

Veracyte sees FY26 revenue $570M-$582M, consensus $565.76M

2026-01-11T22:15:32.000Z - 5 months ago

Veracyte sees FY26 revenue $570M-$582M, consensus $565.76M

Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results

Jan 11, 2026, 4:30 PM EST - 5 months ago

Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results

Veracyte price target raised to $50 from $45 at Guggenheim

2026-01-05T14:30:21.000Z - 5 months ago

Veracyte price target raised to $50 from $45 at Guggenheim

Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 29, 2025, 4:30 PM EST - 5 months ago

Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Veracyte assumed with an Underweight at Morgan Stanley

2025-12-01T21:40:31.000Z - 6 months ago

Veracyte assumed with an Underweight at Morgan Stanley

Veracyte Transcript: Stephens Annual Investment Conference

Nov 20, 2025, 12:00 PM EST - 6 months ago

Veracyte Transcript: Stephens Annual Investment Conference

Veracyte Transcript: Jefferies London Healthcare Conference 2025

Nov 20, 2025, 6:30 AM EST - 7 months ago

Veracyte Transcript: Jefferies London Healthcare Conference 2025

Veracyte Transcript: Wolfe Research Healthcare Conference 2025

Nov 17, 2025, 10:00 AM EST - 7 months ago

Veracyte Transcript: Wolfe Research Healthcare Conference 2025

Veracyte Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 7 months ago

Veracyte Earnings Call Transcript: Q3 2025

Veracyte Quarterly report: Q3 2025

Nov 4, 2025, 4:30 PM EST - 7 months ago

Veracyte Quarterly report: Q3 2025

Veracyte Earnings release: Q3 2025

Nov 4, 2025, 4:30 PM EST - 7 months ago

Veracyte Earnings release: Q3 2025

Veracyte Slides: Q3 2025

Nov 4, 2025, 4:30 PM EST - 7 months ago

Veracyte Slides: Q3 2025

Veracyte Announces Third Quarter 2025 Financial Results

Nov 4, 2025, 4:05 PM EST - 7 months ago

Veracyte Announces Third Quarter 2025 Financial Results

Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing

Nov 3, 2025, 4:15 PM EST - 7 months ago

Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing

Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025

Oct 15, 2025, 5:31 PM EDT - 8 months ago

Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025

Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer

Sep 28, 2025, 4:00 PM EDT - 8 months ago

Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer

Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025

Sep 24, 2025, 9:00 AM EDT - 9 months ago

Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025

Veracyte Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 4:50 PM EDT - 9 months ago

Veracyte Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting

Sep 9, 2025, 9:00 AM EDT - 9 months ago

Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting

Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 29, 2025, 8:30 AM EDT - 9 months ago

Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

Aug 27, 2025, 11:25 AM EDT - 10 months ago

Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test

Aug 26, 2025, 8:30 AM EDT - 10 months ago

Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test

Veracyte Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 10 months ago

Veracyte Earnings Call Transcript: Q2 2025

Veracyte Quarterly report: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 10 months ago

Veracyte Quarterly report: Q2 2025

Veracyte Earnings release: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 10 months ago

Veracyte Earnings release: Q2 2025

Veracyte Slides: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 10 months ago

Veracyte Slides: Q2 2025

Veracyte Announces Second Quarter 2025 Financial Results

Aug 6, 2025, 4:05 PM EDT - 10 months ago

Veracyte Announces Second Quarter 2025 Financial Results

Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025

Jul 17, 2025, 5:30 PM EDT - 11 months ago

Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025

Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025

Jul 8, 2025, 4:05 PM EDT - 11 months ago

Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025

Veracyte Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 2:00 PM EDT - 1 year ago

Veracyte Transcript: Jefferies Global Healthcare Conference 2025

Veracyte Slides: FY 2025

Jun 4, 2025, 2:00 PM EDT - 1 year ago

Veracyte Slides: FY 2025

Veracyte Transcript: 45th Annual William Blair Growth Stock Conference

Jun 3, 2025, 5:40 PM EDT - 1 year ago

Veracyte Transcript: 45th Annual William Blair Growth Stock Conference

Veracyte Slides: 45th Annual William Blair Growth Stock Conference

Jun 3, 2025, 5:40 PM EDT - 1 year ago

Veracyte Slides: 45th Annual William Blair Growth Stock Conference

Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research

May 28, 2025, 4:05 PM EDT - 1 year ago

Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research

Veracyte Earnings Call Transcript: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Veracyte Earnings Call Transcript: Q1 2025

Veracyte Quarterly report: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Veracyte Quarterly report: Q1 2025

Veracyte Earnings release: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Veracyte Earnings release: Q1 2025

Veracyte Slides: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Veracyte Slides: Q1 2025

Veracyte Announces First Quarter 2025 Financial Results

May 7, 2025, 4:05 PM EDT - 1 year ago

Veracyte Announces First Quarter 2025 Financial Results

Veracyte Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Veracyte Proxy statement: Proxy Filing

Veracyte Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Veracyte Proxy statement: Proxy Filing

Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer

Apr 25, 2025, 7:00 AM EDT - 1 year ago

Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer

Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting

Apr 22, 2025, 9:00 AM EDT - 1 year ago

Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting

Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute's SEER Specialized Database Release

Apr 21, 2025, 4:05 PM EDT - 1 year ago

Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute's SEER Specialized Database Release

New Data Demonstrate Accuracy of Veracyte's Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer

Mar 25, 2025, 4:05 PM EDT - 1 year ago

New Data Demonstrate Accuracy of Veracyte's Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer

Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25

Mar 19, 2025, 5:00 PM EDT - 1 year ago

Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25

Veracyte Transcript: Leerink Global Healthcare Conference 2025

Mar 11, 2025, 8:40 AM EDT - 1 year ago

Veracyte Transcript: Leerink Global Healthcare Conference 2025

Veracyte Transcript: Raymond James & Associates’ 46th Annual Institutional Investors Conference 2025

Mar 5, 2025, 9:50 AM EST - 1 year ago

Veracyte Transcript: Raymond James & Associates’ 46th Annual Institutional Investors Conference 2025

Veracyte Slides: FY 2025

Mar 5, 2025, 9:50 AM EST - 1 year ago

Veracyte Slides: FY 2025

Veracyte Earnings Call Transcript: Q4 2024

Feb 24, 2025, 4:30 PM EST - 1 year ago

Veracyte Earnings Call Transcript: Q4 2024

Veracyte Annual report: Q4 2024

Feb 24, 2025, 4:30 PM EST - 1 year ago

Veracyte Annual report: Q4 2024

Veracyte Earnings release: Q4 2024

Feb 24, 2025, 4:30 PM EST - 1 year ago

Veracyte Earnings release: Q4 2024

Veracyte Slides: Q4 2024

Feb 24, 2025, 4:30 PM EST - 1 year ago

Veracyte Slides: Q4 2024

Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results

Feb 24, 2025, 4:05 PM EST - 1 year ago

Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results

New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research

Feb 14, 2025, 8:30 AM EST - 1 year ago

New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research

Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests' Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium

Feb 11, 2025, 8:30 AM EST - 1 year ago

Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests' Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium

New Study Shows Veracyte's Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer

Feb 5, 2025, 8:30 AM EST - 1 year ago

New Study Shows Veracyte's Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer

Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025

Feb 4, 2025, 4:30 PM EST - 1 year ago

Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025

Veracyte's Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines

Dec 5, 2024, 4:05 PM EST - 1 year ago

Veracyte's Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines

Veracyte Transcript: Stephens 26th Annual Investment Conference | NASH2024

Nov 20, 2024, 4:00 PM EST - 1 year ago

Veracyte Transcript: Stephens 26th Annual Investment Conference | NASH2024

Veracyte Transcript: Wolfe Research Healthcare Conference 2024

Nov 19, 2024, 1:40 PM EST - 1 year ago

Veracyte Transcript: Wolfe Research Healthcare Conference 2024

Veracyte Transcript: Guggenheim Inaugural Global Healthcare Innovation Conference

Nov 13, 2024, 3:00 PM EST - 1 year ago

Veracyte Transcript: Guggenheim Inaugural Global Healthcare Innovation Conference

Veracyte Transcript: UBS Global Healthcare Conference 2024

Nov 12, 2024, 2:45 PM EST - 1 year ago

Veracyte Transcript: UBS Global Healthcare Conference 2024

Veracyte Earnings Call Transcript: Q3 2024

Nov 6, 2024, 4:30 PM EST - 1 year ago

Veracyte Earnings Call Transcript: Q3 2024

Veracyte Quarterly report: Q3 2024

Nov 6, 2024, 4:30 PM EST - 1 year ago

Veracyte Quarterly report: Q3 2024

Veracyte Earnings release: Q3 2024

Nov 6, 2024, 4:30 PM EST - 1 year ago

Veracyte Earnings release: Q3 2024

Veracyte Slides: Q3 2024

Nov 6, 2024, 4:30 PM EST - 1 year ago

Veracyte Slides: Q3 2024

Veracyte Announces Third Quarter 2024 Financial Results

Nov 6, 2024, 4:05 PM EST - 1 year ago

Veracyte Announces Third Quarter 2024 Financial Results

Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024

Oct 16, 2024, 6:43 PM EDT - 1 year ago

Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024

New Data Presented at ESMO 2024 Show that Veracyte's Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

Sep 15, 2024, 8:45 AM EDT - 1 year ago

New Data Presented at ESMO 2024 Show that Veracyte's Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

Veracyte Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 5, 2024, 2:35 PM EDT - 1 year ago

Veracyte Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors

Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 26, 2024, 5:30 PM EDT - 1 year ago

Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle

Aug 26, 2024, 9:00 AM EDT - 1 year ago

Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle

Veracyte Earnings Call Transcript: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 1 year ago

Veracyte Earnings Call Transcript: Q2 2024

Veracyte Quarterly report: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 1 year ago

Veracyte Quarterly report: Q2 2024

Veracyte Earnings release: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 1 year ago

Veracyte Earnings release: Q2 2024

Veracyte Slides: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 1 year ago

Veracyte Slides: Q2 2024

Veracyte Announces Second Quarter 2024 Financial Results

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Veracyte Announces Second Quarter 2024 Financial Results

Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024

Jul 17, 2024, 5:00 PM EDT - 2 years ago

Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024

OptionsTrader8364
OptionsTrader8364 Jun. 3 at 6:22 PM
$VCYT bought in- let’s go! Large room for growth
0 · Reply
Nigel11
Nigel11 Jun. 3 at 6:14 PM
$SOFI pay attention to $VCYT
0 · Reply
Following_the_trend
Following_the_trend Jun. 3 at 6:08 PM
$VCYT Continues it's upward move
0 · Reply
whiteavid
whiteavid Jun. 1 at 3:07 PM
$VCYT let’s goooo!!
0 · Reply
whiteavid
whiteavid Jun. 1 at 12:35 PM
$VCYT
0 · Reply
whiteavid
whiteavid Jun. 1 at 11:32 AM
$VCYT investors call in an hour
0 · Reply
whiteavid
whiteavid May. 30 at 2:07 PM
$VCYT bbc interview now
0 · Reply
ChillllinTheMost
ChillllinTheMost May. 29 at 9:36 PM
$VCYT https://www.theguardian.com/society/2026/may/29/groundbreaking-genomic-test-spare-breast-cancer-patients-chemotherapy-hormone-therapy Early next week should be interesting. 🔥
0 · Reply
HodlMaBeer
HodlMaBeer May. 29 at 6:22 AM
$VCYT sweet!! Lt hold wife's account Shes already doubled her position in $APGE
0 · Reply
ChillllinTheMost
ChillllinTheMost May. 28 at 3:38 PM
$VCYT looks like the initial data in the abstract is extremely positive. After the data is presented this weekend, next week should be interesting! Time to accumulate if you haven’t been. Lol. https://www.reuters.com/business/healthcare-pharmaceuticals/veracyte-genomic-test-identifies-breast-cancer-patients-who-can-skip-chemo-2026-05-27/
0 · Reply
GordonGordon
GordonGordon May. 28 at 1:45 PM
$VCYT Anyone know this company well enough to speculate on how their presentations go over the next few days and how wall street and investors might react?
2 · Reply
RockyMontana
RockyMontana May. 24 at 9:06 AM
$PSNL is not in BTK group, but $NTRA $ILMN $VCYT are. Theme matters in this case. I leave the rest to u.
0 · Reply
Alashmax
Alashmax May. 22 at 11:26 AM
$VCYT it's not moving either up or down what's happening?
1 · Reply
ChillllinTheMost
ChillllinTheMost May. 22 at 10:22 AM
$VCYT buckle up, looks like it could be a big week! https://finance.yahoo.com/sectors/healthcare/articles/optima-trial-results-presented-asco-220000946.html
0 · Reply
PhishTourFunds
PhishTourFunds May. 19 at 1:56 AM
$VCYT Done did that
0 · Reply
Following_the_trend
Following_the_trend May. 18 at 6:08 PM
$VCYT So few followers and moving up nicely today.
0 · Reply
Shlobby
Shlobby May. 18 at 5:23 PM
$VCYT send it
0 · Reply
BioTechHealthX
BioTechHealthX May. 17 at 5:44 PM
$VCYT Veracyte is not just another biotech story built on promises. With Q1 2026 revenue up 21%, testing revenue up 26%, and strong growth from Decipher and Afirma, VCYT stock may be one of the cleaner biotech stocks to watch. https://biotechhealthx.com/biotech-news/is-veracyte-vcyt-a-good-diagnostics-stock-to-buy-for-long-term-growth/
0 · Reply
BioTechHealthX
BioTechHealthX May. 17 at 10:49 AM
$CDNA $GRAL $NBIX $TNGX $VCYT For investors searching for the best biotech stocks to buy now, these 5 companies offer exposure to diagnostics, rare disease, cancer screening, RNA medicine, and commercial-stage biotech growth. https://biotechhealthx.com/biotech-news/top-5-biotech-stocks-that-could-climb-as-much-as-100/
0 · Reply
BillionerOfKing
BillionerOfKing May. 11 at 1:16 PM
$VCYT Current Stock Price: $40.44 Contracts to trade: $40.0 VCYT May 15 2026 Call Entry: $2.52 Exit: $3.30 ROI: 31% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BioTechHealthX
BioTechHealthX May. 10 at 5:15 PM
$VCYT Veracyte is gaining attention as a precision medicine stock with rising test volume, 21% revenue growth, positive net income, and expanding cancer diagnostics exposure beyond prostate and thyroid testing. https://biotechhealthx.com/biotech-news/is-it-a-wise-move-to-buy-veracyte-vcyt-shares-today/
0 · Reply
BioTechHealthX
BioTechHealthX May. 10 at 4:21 AM
$ARQT $CDNA $NBIX $VCYT $BHVN These top 5 biotech stocks to buy for May 2026 are not just random healthcare names. With projected EPS growth reaching up to 215%, rising sales expectations, precision medicine exposure, and high-risk, high-reward biotech potential, this list could grab serious investor attention. https://biotechhealthx.com/biotech-news/top-5-biotech-stocks-to-buy-with-up-to-215-projected-eps-growth/
0 · Reply